543 related articles for article (PubMed ID: 25526929)
1. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
2. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
3. [Peculiarity of infantile cystinosis in Tunisian children].
Jellouli M; Ben Turkia H; Abidi K; Hammi Y; Gargah T
Pan Afr Med J; 2015; 22():348. PubMed ID: 26985266
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
[TBL] [Abstract][Full Text] [Related]
5. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
[TBL] [Abstract][Full Text] [Related]
6. [Cystinosis in adults: A systemic disease].
Servais A; Goizet C; Bertholet-Thomas A; Decramer S; Llanas B; Choukroun G; Novo R
Nephrol Ther; 2015 Jun; 11(3):152-9. PubMed ID: 25769364
[TBL] [Abstract][Full Text] [Related]
7. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
8. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
Dohil R; Cabrera BL
Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment of nephropathic cystinosis with cysteamine.
Kleta R; Gahl WA
Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term cysteamine treatment in patients with cystinosis.
Ariceta G; Giordano V; Santos F
Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
[TBL] [Abstract][Full Text] [Related]
12. Nephropathic cystinosis in children: An overlooked disease.
Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
[TBL] [Abstract][Full Text] [Related]
13. Predicted reciprocal serum creatinine at age 10 years as a measure of renal function in children with nephropathic cystinosis treated with oral cysteamine.
Gahl WA; Schneider JA; Schulman JD; Thoene JG; Reed GF
Pediatr Nephrol; 1990 Mar; 4(2):129-35. PubMed ID: 2397178
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
[No Abstract] [Full Text] [Related]
15. Nephropathic cystinosis: late complications of a multisystemic disease.
Nesterova G; Gahl W
Pediatr Nephrol; 2008 Jun; 23(6):863-78. PubMed ID: 18008091
[TBL] [Abstract][Full Text] [Related]
16. Parenchymal organ cystine depletion with long-term cysteamine therapy.
Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
[TBL] [Abstract][Full Text] [Related]
17. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy.
Sonies BC; Almajid P; Kleta R; Bernardini I; Gahl WA
Medicine (Baltimore); 2005 May; 84(3):137-146. PubMed ID: 15879904
[TBL] [Abstract][Full Text] [Related]
18. Extrarenal complications of cystinosis.
Topaloglu R
Pediatr Nephrol; 2024 Aug; 39(8):2283-2292. PubMed ID: 38127152
[TBL] [Abstract][Full Text] [Related]
19. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome.
Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA
Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193
[TBL] [Abstract][Full Text] [Related]
20. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]